Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zhibo Zheng, Siyuan Li, Mohan Liu, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3476-3476
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients’ treatment
V. Lelarge, Remi Capelle, Frédérik Oger, et al.
npj Aging (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 29
CAR-T cell therapy: Where are we now, and where are we heading?
Jiayi Wang, Liang Wang
Blood Science (2023) Vol. 5, Iss. 4, pp. 237-248
Open Access | Times Cited: 28
Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy
Maryam Sahlolbei, Amirhossein Ahmadieh-Yazdi, Mohadeseh Rostamipoor, et al.
IntechOpen eBooks (2024)
Open Access | Times Cited: 5
Recent updates on allogeneic CAR-T cells in hematological malignancies
Shafieeh Mansoori, Ahmad Noei, Amirhosein Maali, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
Yun Chang, Ming‐Yang Chang, Xiaoping Bao, et al.
Bioactive Materials (2024) Vol. 42, pp. 379-403
Open Access | Times Cited: 5
PD1-TLR10 fusion protein enhances the antitumor efficacy of CAR-T cells in colon cancer
Yuzheng Peng, Zhiming Huang, Yafei Wu, et al.
International Immunopharmacology (2025) Vol. 148, pp. 114083-114083
Closed Access
Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation
Hadeer Mohamed Ahmed, Said S. Moselhy, Magda I. Mohamad, et al.
Annals of Hematology (2025)
Open Access
An engineered Palivizumab IgG2 subclass for synthetic gp130 and fas mediated signaling
Christoph Wittich, Julia Ettich, Marcel Hertell, et al.
Journal of Biological Chemistry (2025), pp. 108205-108205
Open Access
Role of T-cells in immunotherapy of pancreatic and colon cancers
Ashni Dudhia, Mia Rajan, Keshav Patel, et al.
Elsevier eBooks (2025), pp. 233-244
Closed Access
CAR T Cells in Lung Cancer: Targeting Tumor-Associated Antigens to Revolutionize Immunotherapy
Sattam Khulaif Alenezi
Pathology - Research and Practice (2025), pp. 155947-155947
Closed Access
CAR-T and Nanotechnology: A Comparative Perspective on Autoimmune Disease and Cancer
A.J. Pavithra, Chinnasamy Ragavendran
Advances in Biomarker Sciences and Technology (2025)
Open Access
Mechanisms Underlying Resistance to CAR-T Cell Therapy and Strategies for Enhancement
Anran Wu, Tingying Zhang, Hongkai Yu, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access
Overview of tumor immunotherapy based on approved drugs
Ziqin Chen, Tiantian Hu, Jing Zhou, et al.
Life Sciences (2024) Vol. 340, pp. 122419-122419
Closed Access | Times Cited: 3
A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
Alain E. Andrea, Andrada Chiron, Guillaume Sarrabayrouse, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Chimeric antigen receptors: “CARs” in the fast lane for rheumatology
Nathan M. Johnson, Fotios Koumpouras
Current Opinion in Rheumatology (2024) Vol. 36, Iss. 3, pp. 176-183
Open Access | Times Cited: 2
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity
Thu Nguyen, R Müller, Daria Briukhovetska, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2608-2608
Open Access | Times Cited: 2
PTPRZ1-targeting RNA CAR T cells exert antigen-specific and bystander antitumor activity in glioblastoma
Darel Martinez Bedoya, Eliana Marinari, Suzel Davanture, et al.
Cancer Immunology Research (2024) Vol. 12, Iss. 12, pp. 1718-1735
Closed Access | Times Cited: 2
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives
Jincai Zhou, Bixia Lei, Feifei Shi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Exploring the potential of the convergence between extracellular vesicles and CAR technology as a novel immunotherapy approach
O. Bar, Angel Porgador, Tomer Cooks
Journal of Extracellular Biology (2024) Vol. 3, Iss. 9
Open Access | Times Cited: 1
Nanoparticle-mediated universal CAR-T therapy
Mingliang Fan, Jiayu Zheng, Yue Huang, et al.
International Journal of Pharmaceutics (2024), pp. 124779-124779
Closed Access | Times Cited: 1
Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery
Theodora Katopodi, Savvas Petanidis, Doxakis Anestakis, et al.
Pharmaceutics (2023) Vol. 15, Iss. 10, pp. 2458-2458
Open Access | Times Cited: 2
Finding Your CAR
Po‐Han Chen, Rianna Raghunandan, Jon S. Morrow, et al.
American Journal Of Pathology (2024) Vol. 194, Iss. 8, pp. 1409-1423
Closed Access
CAR-T: from bench to bedside
Marina Popova, Vladislav V. Markelov
Oncohematology (2024) Vol. 19, Iss. 3, pp. 185-198
Open Access
Types of Immunotherapy, Mechanism of Action and Side Effects
Birsen Sahip, Şehmus Ertop, Müzeyyen Aslaner Ak, et al.
(2024), pp. 11-24
Closed Access
Resistance to chimeric antigen receptor T cells (CAR-T)
Ramazan Kaşmer, Nihal Karakaş
Elsevier eBooks (2024), pp. 275-292
Closed Access
Page 1 - Next Page

Scroll to top